Filing Details
Kairos Pharma, LTD. (AMEX:KAPA) filed a Form 8-K with the Securities and Exchange Commission on July 15, 2026, disclosing a material event.
8k filedAMEX:KAPA
Kairos Pharma, LTD. (KAPA) Reports Material Event to SEC
Filing Details Kairos Pharma, LTD. (AMEX:KAPA) filed a Form 8-K with the Securities and Exchange Commission on July 15, 2026, disclosing a material event. Market Context Kairos…
Market Context
Kairos Pharma, LTD.'s stock currently trades at $0.32 with a market capitalization of $16.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Kairos Pharma, LTD.'s stock.
All SEC filings for Kairos Pharma, LTD. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View KAPA Stock Page
Frequently Asked Questions
Where can I read KAPA's SEC filings?
Browse all filings on our KAPA SEC filings page.
What types of SEC filings does Kairos Pharma, LTD. file?
Public companies like Kairos Pharma, LTD. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.